ShangPharma Innovation and the University of California San Francisco Announce Strategic Research Collaboration
-- New innovation group and leading medical center partner on novel approach to advance therapies across the often overlooked early-stage gap in biomedical research --
Jul 13, 2017, 11:00 ET
SAN FRANCISCO and SOUTH SAN FRANCISCO, Calif., July 13, 2017 /PRNewswire/ -- In a new collaboration, ShangPharma Innovation, Inc. (SPII) is providing funding and other support to scientists at UC San Francisco (UCSF) to accelerate the development of promising life science inventions.
The partnership helps advance a major new initiative at UCSF to bridge academic research with industrial development. Part of this effort, which SPII will support, involves backing preclinical research to validate drug targets and to develop programs to discover new drugs. Drugs that UCSF and SPII determine to be promising in preclinical studies can then be readied for clinical trials to demonstrate safety and efficacy in patients.
The collaboration agreement anticipates that SPII will provide several years of funding to carry out R&D in UCSF laboratories. SPII also will commit to spend additional amounts each year during the term of the collaboration to purchase Contract Research Organization (CRO) services in support of the projects being conducted by SPII and UCSF. CRO services will be provided by Shanghai ChemPartner Co. Ltd. (ChemPartner). SPII and UCSF will share in future value created through this innovative partnership.
"When the proper bridges to fundamental research are built, important new medicines reach the marketplace, saving and improving lives around the world," said Walter H. Moos, PhD, CEO of SPII and adjunct professor of pharmaceutical chemistry at UCSF. "We have only just begun to scratch the surface of what's possible when academia and early-stage investors come together to advance novel discoveries. We look forward to enabling biomedical innovation across all borders and disciplines."
Cathy Tralau-Stewart PhD, interim director of UCSF's Catalyst Program and adjunct associate professor of bioengineering and therapeutics at UCSF, said, "The translation of early research into novel therapeutics for patients requires a wide range of expertise and capabilities. This collaboration will give UCSF access to the broad range of expertise and services required and will enable the translation of more UCSF discoveries to product opportunities with real potential benefit for patients. This is an important collaboration and we look forward to working closely with the ShangPharma and ChemPartner teams."
About ShangPharma Innovation
ShangPharma Innovation, Inc., founded in the US in 2016, facilitates and accelerates drug discovery, focusing on both therapeutics and technology platforms, and offers funding, incubator space, and other support to its ecosystem of collaborators, partners, and tenants. This includes sponsoring proof-of-concept research at major academic and medical centers, research institutes, and seed-stage start-ups, leading to industry collaborations and venture capital financing. ShangPharma Innovation and ChemPartner are affiliates and preferred partners. Services will be provided predominantly or solely by ChemPartner at their standard commercial rates. For more information, see http://www.shangpharmainnovation.com.
About UCSF
UC San Francisco (UCSF) is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, translational and population sciences; and a preeminent biomedical research enterprise. It also includes UCSF Health, which comprises top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children's Hospitals in San Francisco and Oakland - and other partner and affiliated hospitals and healthcare providers throughout the Bay Area. Please visit www.ucsf.edu/news.
The Catalyst program, which is part of UCSF's Innovation Ventures, accelerates translation of research into products with clinical impact through funding, mentorship, and identification of resources. Catalyst aims to foster academic and industry collaborations as well as enhance education in early translational research and entrepreneurship. See http://ctsi.ucsf.edu/catalyst.
About ChemPartner
Shanghai ChemPartner Co. Ltd., along with its subsidiary entities, is a leading research organization providing high-quality and cost-effective contract research services for the biopharmaceutical industry. ChemPartner offers integrated services across the drug discovery and development process to pharmaceutical and biotechnology companies worldwide. ChemPartner's dedication to life science is seen through its broad range of services, from discovery biologics, discovery chemistry, discovery biology, and preclinical development through pharmaceutical development and manufacturing services for small molecules and biologics. For more information, see http://www.chempartner.com.
FOR MORE INFORMATION
ShangPharma Innovation, Inc.
[email protected]
SOURCE ShangPharma Innovation